Novartis secures rights to Mesoblast’s remestemcel-L for ARDS
Drug is currently being evaluated in a phase III COVID-19-related ARDS study
Read More
Tag: Acute respiratory distress syndrome
Faron stock falls on traumakine failure
Shares Finnish group Faron Pharmaceuticals were trading down more than 80 percent on the London Stock Exchange after its key drug traumakine failed in acute respiratory distress syndrome (ARDS).
Read More
